The Pfizer Boss’s Statement is up to the preparation of drug manufacturers for the possible American introduction of customs duties of 25 percent on the import of drugs.
The company with a production network in the US will be better to pass to transfer production to the home country to avoid customs, Bourla said on Monday at TD Cowen Health Conference TD Cowen.
“We have capacities in the US and production sites are currently working in good capacity. If something happens, we will try to alleviate it with a relocation from production locations abroad here in the USA,” he added.
Pfizer in the USA has ten production sites and two distribution centers.
Trump promised in the election campaign to encourage domestic production, and the pre-Europeans indicated that he could introduce a duty of 25 percent and the import of drugs, reminders Reuters.
In February, the US president met with the executive directors of large drug producers, including Head of Eli Lilly David Ricks. Among the topics of the meeting were also fears of companies from import customs.
Eli Lilly announced last week that he plans to invest at least $ 27 billion in the construction of four production facilities in the home USA.
The new plants will be built in the next five years and will open more than 3,000 jobs for highly qualified workers, such as engineers and scientists, and 10,000 on construction affairs.
The locations will be published by the end of the year, they added.
Eli Lilly will produce pharmaceutical raw materials in three new plants, and in the fourth drug for intravenous application.
(Vijesti.ba)
